

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/869,142	AOKI ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Christian L Fronda	1652	

All participants (applicant, applicant's representative, PTO personnel):

(1) Christian L Fronda. (3)\_\_\_\_\_.

(2) Mark Hayman. (4)\_\_\_\_\_.

Date of Interview: 29 June 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 8,10,11 and 60-72.


Identification of prior art discussed: Kato et al.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.



Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Claim rejections stated in the previous Office Action were discussed. Applicants provided arguments to overcome the claim rejections under 35 U.S.C. § 112, 1st Paragraph and 35 U.S.C. § 102. Applicants cite Example 1 of the specification where *Rhodococcus* strains were treated with a chemical mutagen, N-methyl-N'-nitrosoguanidine, and Examples 2-19 where *Rhodococcus* strains were transformed with polynucleotides encoding nitrile hydratase and amidase. Applicants' arguments and submission of the Amendment Under 37 C.F.R. § 1.111 will be considered prior to issuance of the next Office Action..